Network meta-analyses in IBD suggest that TNF antagonists may be the most efficacious for management of moderate to severe CD, whereas vedolizumab and infliximab may be equally efficacious for patients with moderate to severe UC.18,19 However, older patients are underrepresented in these clinical trials. The gene discussed is TNF; the disease is inflammatory bowel disease.